Lineage Cell Therapeutics(LCTX)

Focus: Lineage Cell Therapeutics is a public regenerative medicine biotech focused on cell therapy for spinal cord injuries and other conditions. The company operates as a clinical-stage developer with minimal revenue and high R&D burn.

Unknown

Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Lineage Cell Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Lineage Cell Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$9M

FY2025

Pipeline & Clinical Trials

Magnetic Resonance Imaging

Spinal Cord Injuries

N/A

Clinical Trials (1)

NCT05919563LTFU Study of Subjects Who Received GRNOPC1

N/A

Help build intelligence for Lineage Cell Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer regenerative medicine platform with multiple Phase 1/1-2 programs in spinal cord injury, a large unmet medical need
Public company status provides equity upside potential and established governance infrastructure
Focused pipeline allows deep specialization in cell therapy manufacturing and clinical development

Watch Out For

Minimal revenue ($9M FY2025) with significant operating losses ($18.6M net loss FY2025) creates financial sustainability risk
Currently zero active job openings signals reduced hiring and potential organizational constraints
No Phase 3 programs in pipeline means earliest potential regulatory approval is years away with high clinical risk

Generated by Claude from Lineage Cell Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Magnetic Resonance Imaging

Spinal Cord Injuries

N/A

Clinical Trials (1)

NCT05975424LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1

N/A

GRNOPC1

Spinal Cord Injury

PHASE_1

Clinical Trials (1)

NCT01217008Safety Study of GRNOPC1 in Spinal Cord Injury

Phase 1

OPC1

Spinal Cord Injury Cervical

PHASE_1

Clinical Trials (1)

NCT06841770A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury

Phase 1

AST-OPC1

Cervical Spinal Cord Injury

PHASE_1_2

Clinical Trials (1)

NCT02302157Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$9M6%

R&D Spend

$12M(131%)21%

Net Income

-$19M

Cash

$46M

Source: SEC 10-K Filing

Lineage Cell Therapeutics(LCTX)

About Lineage Cell Therapeutics

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Lineage Cell Therapeutics(10)

Open Jobs (0)

Financials (FY2025)